Literature DB >> 18520952

Rapid kinetic interactions of ranolazine with HERG K+ current.

Sridharan Rajamani1, John C Shryock, Luiz Belardinelli.   

Abstract

Ranolazine, an anti-ischemic agent, inhibits I Kr [encoded by the human ether-a-go-go-related gene (HERG)] and causes a small QT interval prolongation without any proarrhythmic events. The objective of this study was to elucidate the biophysical characteristics of inhibition of HERG K+ current (IHERG) by ranolazine. We investigated the effects of ranolazine using voltage-clamp and Western blot analyses of HERG channels stably expressed in HEK293 cells. Ranolazine reduced IHERG with the half-maximal inhibitory concentration of 12.0 microM. Block of IHERG by ranolazine was reversible and voltage-dependent but frequency-independent. At 0 mV, the time constants for development of block were 76.6 +/- 1.6, 35.8 +/- 2.4, and 19.4 +/- 1.7 msec with 10, 30, and 100 microM ranolazine (n = 4), respectively. The apparent dissociation constant estimated from the time course of ranolazine-induced IHERG decay was 22.5 microM. After repolarization at -80 and -100 mV, IHERG recovery from ranolazine block followed a monophasic time course with tau values of 204.3 +/- 51.5 and 155.0 +/- 31.9 msec (n = 5), respectively. Intracellular but not extracellular application of a membrane-impermeable (permanently charged) ranolazine analogue caused rapid block of IHERG. Ranolazine did not alter HERG protein trafficking to the plasma membrane. In conclusion, ranolazine caused a time- and voltage-dependent, but frequency-independent, block of IHERG. The kinetics of IHERG inhibition (at positive potentials) and unblock (upon hyperpolarization) by ranolazine were rapid. These distinct and rapid kinetic interactions of ranolazine with IHERG may partially contribute to the observations that the drug is not proarrhythmic despite causing a small prolongation of action potentials and QT intervals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520952     DOI: 10.1097/FJC.0b013e3181799690

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  23 in total

1.  In silico assessment of drug safety in human heart applied to late sodium current blockers.

Authors:  Beatriz Trenor; Julio Gomis-Tena; Karen Cardona; Lucia Romero; Sridharan Rajamani; Luiz Belardinelli; Wayne R Giles; Javier Saiz
Journal:  Channels (Austin)       Date:  2013 Jul-Aug       Impact factor: 2.581

Review 2.  [Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation].

Authors:  David Filgueiras-Rama; Sergio Castrejón; Conrado Calvo; Alejandro Estrada; David Doiny; Marta Ortega; Omer Berenfeld; José L Merino; José Jalife
Journal:  Arch Cardiol Mex       Date:  2012 Apr-Jun

3.  Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.

Authors:  Ashish Parikh; Rajkumar Mantravadi; Dmitry Kozhevnikov; Michael A Roche; Yanping Ye; Laura J Owen; Jose Luis Puglisi; Jonathan J Abramson; Guy Salama
Journal:  Heart Rhythm       Date:  2012-01-11       Impact factor: 6.343

4.  18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.

Authors:  Yi-mei Du; Cheng-kun Xia; Ning Zhao; Qian Dong; Ming Lei; Jia-hong Xia
Journal:  Acta Pharmacol Sin       Date:  2012-05-21       Impact factor: 6.150

5.  Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.

Authors:  Kristopher M Kahlig; Irene Lepist; Kwan Leung; Sridharan Rajamani; Alfred L George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

6.  Late sodium current (INaL) in pancreatic β-cells.

Authors:  Riccardo Rizzetto; Marcella Rocchetti; Luca Sala; Carlotta Ronchi; Alice Villa; Mara Ferrandi; Isabella Molinari; Federico Bertuzzi; Antonio Zaza
Journal:  Pflugers Arch       Date:  2014-09-20       Impact factor: 3.657

Review 7.  Pathophysiology of the cardiac late Na current and its potential as a drug target.

Authors:  Jonathan D Moreno; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2011-12-16       Impact factor: 5.000

8.  Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.

Authors:  Mark Estacion; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Mol Pain       Date:  2010-06-08       Impact factor: 3.395

9.  Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.

Authors:  C H Peters; S Sokolov; S Rajamani; P C Ruben
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.

Authors:  Jennifer L Smith; Allison R Reloj; Parvathi S Nataraj; Daniel C Bartos; Elizabeth A Schroder; Arthur J Moss; Seiko Ohno; Minoru Horie; Corey L Anderson; Craig T January; Brian P Delisle
Journal:  Am J Physiol Cell Physiol       Date:  2013-07-17       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.